Lantern Pharma Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2019 to Q3 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Lantern Pharma Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2019 to Q3 2024.
- Lantern Pharma Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$4.51M, a 42.5% decline year-over-year.
- Lantern Pharma Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$19.1M, a 26% decline year-over-year.
- Lantern Pharma Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$16M, a 11.9% decline from 2022.
- Lantern Pharma Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$14.3M, a 15.3% decline from 2021.
- Lantern Pharma Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$12.4M, a 109% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)